EAR - Fulcrum stock leads weekly healthcare gains; Axsome Sesen Bio among laggards

Having reached a two-week low in the middle of the week, healthcare stocks in the S&P 500 rose two consecutive sessions to gain ~0.5% over the past five days. Yet, that was not enough to edge past the ~0.7% weekly gain in the broader index. Most healthcare stocks with the sharpest moves this week were driven by earnings results or surprise business updates therein. However, thanks to positive early-stage results for its sickle cell disease candidate, Fulcrum Therapeutics (NASDAQ:FULC) gained ~183.1% over the week to become the best performer among healthcare stocks (with more than $300M market cap and over 100K average daily volume). Meanwhile, Cortexyme (NASDAQ:CRTX) surged ~49.1% after the company issued an update with its Q2 2021 results to forecast a November readout of topline data from a pivotal study for atuzaginstat, its candidate for Alzheimer's disease. Recently IPO’ed Doximity (NYSE:DOCS), a digital platform for healthcare professionals, followed up with a ~45.2% gain after its better than expected

For further details see:

Fulcrum stock leads weekly healthcare gains; Axsome, Sesen Bio among laggards